newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3